Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Reduced by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,285 shares of the biopharmaceutical company's stock after selling 3,790 shares during the quarter. Teacher Retirement System of Texas' holdings in Alnylam Pharmaceuticals were worth $9,528,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ALNY. Investment Management Corp of Ontario increased its position in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock valued at $1,670,000 after purchasing an additional 40 shares during the last quarter. Brevan Howard Capital Management LP increased its position in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 44 shares during the last quarter. National Bank of Canada FI increased its position in shares of Alnylam Pharmaceuticals by 9.0% during the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock valued at $157,000 after purchasing an additional 55 shares during the last quarter. Washington Trust Advisors Inc. increased its position in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 61 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ALNY has been the topic of several analyst reports. Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research report on Monday, June 30th. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective on the stock. Finally, Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $341.91.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $3.37 on Wednesday, reaching $320.87. The company had a trading volume of 1,039,475 shares, compared to its average volume of 857,162. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The company's fifty day moving average is $298.71 and its 200 day moving average is $267.72. The company has a market cap of $41.84 billion, a P/E ratio of -153.53 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the previous year, the company earned ($0.16) earnings per share. The company's quarterly revenue was up 20.2% on a year-over-year basis. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.